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- 6 - 
 
ABSTRACT 
Angiogenesis is the extension of new blood vessels from the preexisting vessels. This 
mechanism occurs in pathological conditions of the CNS such as stroke, brain tumors 
or neurotrauma. After ischemic stroke and brain injury, angiogenesis tries to restore 
tissue perfusion by developing new vessels. VEGF was traditionally regarded as the 
primary factor activated in the angiogenic reparation and it has been proposed to in 
the therapy of neurodegenerative diseases. Unfortunately, the VEGF is not a good 
drug candidate for its pharmacokinetic limitations and its capacity to permeabilize the 
cerebral endothelium causing brain leakage. Due to the increasing evidences from 
literature showing an involvement of autophagy in new vessels formation it has been 
verified whether autophagy could have a role in blood vessel formation in a 
pathological condition where the failure to supply blood to suffering brain is crucial, the 
ischemic stroke. There are different conditions in the brain that promote autophagy 
such as oxygen deprivation with activation of angiogenesis. To test our working 
hypothesis, in vitro experiments were performed in order to evaluate whether 
autophagy could be involved in vitro tubulogenesis by modulating the autophagic 
cascade. In these experiments, brain endothelial cells (bEND5) VEGF independents 
and forming a capillary-like network when plated on Matrigel, were used. Hereafter, it 
has been evaluated if the experimental hypothesis tested in vitro experiments could be 
confirmed also in vivo experiments in rodents thus allowing us to verify whether 
autophagy could be considered a mechanism involved in angiogenesis and therefore 
it could be proposed as a target for the therapy of stroke. 
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PREMISE 
Still today ischemic stroke continues to represent the third leading cause of death in 
the western world. This cerebral insult is the leading cause of permanent disability with 
enormous costs in terms of suffering for patients and their caregivers. At present, the 
available therapies for the treatment of stroke do not appear satisfactory and there is 
an unmet medical need for effective therapies for that pathology. The Central Nervous 
System is a breakable organ and easily damage to the ischemic events. Stroke is 
caused by an interruption of blood flow to the brain that can occurs in two different 
mechanisms: the first, is due by a formation of a thrombus that block the cerebral 
artery; the second is a rupture of the cerebral vessel that causes hemorrhage and its 
fatal. Unfortunately, for logistical reasons it is often impossible to guarantee such a 
timely therapeutic intervention. In perspective, therefore, therapeutic approaches of 
regenerative medicine appear, which aim to intervene on the damage already realized 
to promote its repair. In the present experimental project, the objective is intended to 
acquire new information on the molecular mechanisms of such reparative processes 
and could lead to the identification of new approaches for their pharmacological 
activation. In this time, the only approved treatment is represented by vasal 
recanalization with the tissue plasminogen activator (tPa) or its derivatives which, 
however, are effective only if administered within a very narrow time window (between 
3 and 6 hours) after the ischemic event. These drugs act by preventing neuronal death 
by early recovery of the circle while they are ineffective on the damage already 
established.  
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I.  INTRODUCTION 
I.1. Vasculogenesis and Angiogenesis: an overview 
In the early stages of development, the human embryo receives nutrients and oxygen 
through the diffusion process. In the successive phases, the embryo undergoes to a 
rapid formation of a circulatory system constituted by a complex network of capillary 
and blood vessels that procure the transport of oxygen and nutrients to the various 
organs and tissues in the body. This initial phase of vessel formation in the embryo is 
called "Vasculogenesis" and starts from the hemangioblasts which are mesodermal 
cells derived from the extra-embryonic yolk sac of which proliferate and differentiate 
into angioblasts by Notch signals and for the follow “arterial-venous” cell fate 
transformation, it depends by on one of the two transmembrane proteins that they can 
have during the step of angioblast transformation, in which the first transmembrane 
protein is Ephrin-B2 for an arterial cell fate and from their aggregation generating the 
dorsal aorta, and the second is EphB4 for a venous cell fate that by their aggregation 
forming the cardinal vein. From the fusion of these two types of blood vessels there is 
the formation of the Primary capillary plexus which evolves in a complete circulatory 
system as shown in the Figure 1 (Chung and Ferrara 2011). The sprouting of new 
blood vessels from pre-existing vessels is stabilized by the recruitment of mural cell 
(Pericytes and Smooth-muscle cells) that proliferate and differentiate in response to 
Angiopoietins and to the TGF-β (Transforming Growth Factor-β) signaling and, in turn, 
are recruited to vessels by PDGF-B (Platelet-Derived Growth Factor B). This second 
stage of formation of new blood vessels from pre-existing vessels is termed 
“Angiogenesis” and this definition was introduced by John Hunter in 1794, to describe 
blood vessel growth in reindeer antlers. 
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Figure 1. A schematic representation of developmental vasculogenesis and angiogenesis during 
early stages of development in the human embryo: In the first step of vessel formation (A) the 
hemangioblast precursors are marked by the Flk-1 that can generate the hematopoietic cells, or by 
Notch signaling become the angioblasts. They for a follow Notch signaling, can aggregate forming two 
types of vessels that depends from two signals that are: (B) Ephrin-B2 for the dorsal aorta (red) and 
EphB4 for the cardinal vein (blue). This aggregation mediated by signaling as VEGF, SHH and DLL 
(Delta-like ligand) conduces to the formation of primary capillary plexus (C). For a vascular remodeling, 
mural cells are recruited and initiate the process of vessels sprouting mediated by PDGF-B, TGF-β and 
ANG-1 to form the capillary bed (D) (Chung and Ferrara 2011). 
 
In addition to these two terms of “vasculogenesis” and “angiogenesis”, the term 
neoangiogenesis is also used to describe the de novo formation of new blood vessels 
that is common in tumors where it contributes to nutrient supply both in primary tumors 
and in metastasis. This formation derives from either interstitial precursors or stem 
cells coming from peripheral circulation. 
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I.1.1. Angiogenesis in the Central Nervous System 
Central Nervous System (CNS) is a very complex organ that is supplied by a highly 
specialized vessels network configured to bring oxygen and nutrients through blood for 
the energetic requests of this metabolically highly active organ mainly constituted by 
the brain. The functions of cerebral circulation are controlled by cells involved in the 
neurovascular unit (NVU), that through their physical interaction form the Blood Brain 
Barrier (BBB) (Figure 2).  
                
Figure 2. Focus on the BBB at the level of NVU: A) The structure of BBB. B) In addition to the cell-
cell adherent junctions, endothelial cells form complex tight junctions through the interaction of several 
transmembrane crucial for the maintenance of brain integrity (Cecchelli, Berezowski et al. 2007). 
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In particular, the endothelial cells are kept in contact by the tight junctions (TJ) and the 
junctional adhesion molecules (JAMs) forming a continuous vessel structure. The 
junctions are transmembrane proteins and accessory cytoplasmic proteins that are 
located on the endothelium (Stamatovic, Keep et al. 2008). The essential function of 
BBB is the protection of the CNS integrity, by orchestrating different mechanisms such 
as ion regulation, balancing of neurotransmitters, by preventing the passage of both 
macromolecules and neurotoxins in the brain through the blood. (Cecchelli, 
Berezowski et al. 2007, Vallon, Chang et al. 2014). In pathological conditions of the 
CNS such as brain tumors, neurodegenerative diseases and arteriovenous 
malformations, angiogenesis is activated. For years, the growth of gliomas in CNS, has 
been identified with neoangiogenesis since this phenomenon was considered to be 
restricted only to the brain. More recently, it has become clear that angiogenesis also 
plays a role in non-neoplastic neurological diseases such as cerebral ischemia, 
neurotrauma and epilepsy. From the beginning of the 20th century, vascular anomalies 
and blood deficiency have been suspected of contributing to epileptogenesis 
(Bratz,1899, Spielmeyer,1927) and significant changes in blood flow have been 
described in the epileptic (Lennox and Gibbs 1932).  
 
I.1.2. Angiogenesis after ischemic stroke 
Among neurovascular multifactorial diseases that affect the brain a central role has the 
ischemic stroke, a pathological condition caused by an obstruction or rupture of a blood 
vessel causing a destabilization of the transport of nutrients and oxygen in the brain 
with neurologic deficit or death. Common causes of stroke are the follows: non-
thrombotic occlusion of small, deep cortical arteries, embolism due to cardiac sources; 
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arterial thrombosis with hemodynamic disturbance leading to decrease of cerebral 
blood flow; artery to artery embolism. In response to this insult, reparative processes 
known as neurogenesis begin to activate in the brain which aim to reconstruct the 
tissue that was destroyed by replacing it with newly formed brain tissues (Beck and 
Plate 2009, Liman and Endres 2012). It is well established that the activation of this 
neurogenesis is elicited by the activation of the NVU that together to the angiogenesis 
is able to restore the blood flow It has been demonstrated that in the subventricular 
zone (SVZ) angiogenesis and neurogenesis are two closely related processes. The 
SVZ contain neural progenitor cells which are close to endothelial cells and during 
neurogenesis are differentiated in neuroblast and later in neurons through soluble 
factors that are secreted by endothelial cells. Other studies have reported an 
association between neurogenesis and vascular marker as CD31 after a stroke (Wang, 
Zhang et al. 2004, Jin, Wang et al. 2006, Ohab, Fleming et al. 2006). CD31 is an 
endothelial cell junctional protein also known as PECAM-1 important for the 
contribution to the maintenance of the endothelial cell permeability barrier. In addition 
to this function, CD31 is involved in the cell migration and angiogenesis 
(Lertkiatmongkol, Liao et al. 2016). For this functions, this is considered as a marker 
for endothelial cells and for a vessel structure in a immunofluorescence staining 
(DeLisser, Newman et al. 1993, DeLisser, Christofidou-Solomidou et al. 1997). 
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I.1.3. Molecular mechanisms of new vessel sprouting 
In normal and quiescent conditions, the physiology of vessel is ruled by a balance 
between pro- and anti- angiogenic factors. When a stimulus like hypoxia is triggered, 
this balance becomes impaired activating the vessels sprouting mechanisms. 
Anatomical structure of the blood vessel is constituted from a monolayer of endothelial 
cells colligated by junctional molecules (claudins and VE- cadherin) which are 
protected from the insults by the autocrine actions of signal such as VEGF, Notch, 
FGF’s and Ang-1 released from pericytes. Therefore, when the vessel detects an 
angiogenic signal (VEGF, FGF’s, chemokines), the pericytes separate from blood 
vessel and endothelial cells begin liberating from the junction causing a vasodilatation 
of blood vessel. Subsequently VEGF inducing an increase of permeability of the 
endothelial cells layer causing an emission of extracellular matrix that provide to 
constitute a scaffold for to build a new tube (Ferrara 2000, Ferrara, Gerber et al. 2003, 
Carmeliet and Jain 2011). Summarizing angiogenic process occurs in several steps: 
1) Angiogenic stimulus; 2) Endothelial Sprouting; 3) Vascular Branching and 
Elongation; 4) Lumen formation and anastomosis; 5) Vessel maturation and 
Intussusception or splitting angiogenesis (Figure 3). 
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Figure 3. Schematic angiogenetic process observed in a blood vessel during physiological 
conditions: After an angiogenic stimulus (1) due by Hypoxia, Inflammatory cells or VEGF, the Pericytes 
separate from the vessel and the permeability of the vessel increases. The MMP (Matrix -
Metalloproteinases) degrade the collagen and other components of the extracellular matrix that 
evenlope the vessel with a disruption of the barrier allowing the Endothelial Cells (EC) migration for an 
endothelial sprouting (2) that continues in the vessel elongation (3) by different mechanism as sprouting 
or intussusception (4) and by the PDGF-B the mural cells are recruited for the vessel maturation with a 
complete formation of the vessel (Logsdon, Finley et al. 2014). 
 
The new vessel sprouting can occur in different modes as follows: sprouting 
angiogenesis, vasculogenesis, intussusception, vessel co-option, vascular mimicry, 
tumor cell-EC differentiation (Figure 4), and the causes that triggers these different 
mechanisms of new vessel formation is not well understood. 
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Figure 4. Different types of vessel sprouting : (A) It is represented the traditional vessel expansion 
known as angiogenesis while the figure (B) is the vasculogenesis;(C) the intussusception is a mode of 
capillary formation in which there is a creation of a central perforation and fusion of the cellular bilayer, 
the endothelial cells form a wall separating the two new vessels formed (Kurz, Burri et al. 2003). (D) this 
model of sprouting happens when tumor cells take possession of the existing vasculature; (E) for 
instance aggressive cancer cells are able to form an alternative vascular network involving endothelial 
cells with a phenomenon called mimicry (Carmeliet and Jain 2011). 
 
I.1.3.1. VEGF contribution to angiogenesis 
In 1989, Ferrara and Henzel and Ploüet independently reported the genomic 
sequencing of the first regulator of angiogenesis by the isolation of an endothelial cell 
specific mitogen, they called VEGF, from medium conditioned from bovine pituitary 
follicular cells (Ferrara and Henzel 1989, Plouet, Moro et al. 1997). The VEGF mitogen 
family includes the VEGF-A (or VEGF, the originally identified), VEGF-B, VEGF-C, 
VEGF-D, VEGF-E and PlGF. In addition, alternative VEGF isoform resulted by the 
differential splicing of the VEGF gene: VEGF121, VEGF145, VEGF165, VEGF1831 
VEGF189 and VEGF206. The difference between each other is on the C-terminal region 
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which is the binding determinant for heparin, encoded for by exons 6 and 7. The 
different members of the VEGF family exert their biological activities through the family 
of specific of binding to a receptors family: VEGFR1-(Flt1); VEGFR2 (Flt1/KDR) that is 
mainly expressed in activated endothelial cells and their embryonic precursors and is 
required for angioblastic differentiation (during vasculogenesis); and VEGFR-3 is 
predominantly expressed in lymphatic endothelium (Figure 5). VEGFR-2 is the most 
responsible for the majority of angiogenic effects activated by VEGF. VEGF is involved 
in the development and spread of many diseases as in neoangiogenesis as it plays an 
essential for tissue repairing and is required for the growth and metastasis of all solid 
tumors.  
 
 
 
Figure 5. Schematic representation of the VEGF-VEGFR system (Olsson, Dimberg et al. 2006). 
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As shown in the Figure 5, VEGF-A, VEGF-B and PlGF bind to VEGFR1, VEGF-A and 
VEGF-E bind VEGFR2, and VEGF-C and VEGF-D bind VEGFR3. VEGF and its 
receptor are expressed in pre- and post-natal neurons that after an insult, for example 
a stroke, their expression increases. Of these, VEGF-A is the only one with the most 
attention for its biological activity and for its only hypoxia-dependent angiogenic 
mediator (Ferrara, Gerber et al. 2003).  
 
I.1.3.1.1. Role of VEGF on angiogenesis after stroke  
VEGF is involved in many important processes of the central nervous system and for 
this it was traditionally regarded as the primary factor activated in the angiogenetic 
reparation and it has been proposed to use in the therapy of neurodegenerative 
diseases (Greenberg and Jin 2013). Many studies on rodents, demonstrated that after 
stroke, there is an increased expression of VEGF in ischemic brain that contributes to 
the repair of brain ischemic regions by activating the neurovascular niche. It has been 
suggested that VEGF could represent a useful therapeutic strategy for the treatment 
of stroke. Since encouraging results have been obtained in experimental model of 
stroke in rodents showing that post ischemic administration of VEGF promotes 
angiogenesis. Nevertheless, high doses of VEGF administrated led to significantly 
increased BBB permeability that can worsen the ischemic lesions (Zhang, Zhang et al. 
2000, Singh, Sharma et al. 2012). These unsuccessful events due from the VEGF 
administration raises an interest in the research to identify new mechanisms that can 
repair the damages caused by ischemic stroke without causing the same events of 
VEGF.   
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I.1.3.1.1.1. HIF involved in the activation of VEGF and autophagic process  
The factor mainly responsible for the activation of post ischemic endothelial 
proliferation is the VEGF whose synthesis is regulated by HIF-1 which is activated in 
response to a cerebral ischemic insult (Marti, Bernaudin et al. 2000, Beck and Plate 
2009). HIF-1 is structured as an α-β heterodimer and the α subunit is the determining 
factor for the principal activity of HIF-1 that depends from the oxygen. During a stroke 
causing oxygen deprivation and damage to the tissues, HIF-1 activates different genes 
involved in angiogenesis for restore the flux of oxygen in particularly VEGF (Singh, 
Sharma et al. 2012). As previously suggested that VEGF's administration in the 
treatment of post ischemia has not been successful for its pharmacokinetic properties 
and for its toxicity (induces a permeabilization of the blood brain barrier) that 
discourage the development and the use of VEGF as a drug and for these limitations 
there is interest to identify the mechanism for the regeneration of ischemic tissue 
activating the neuro-vascular niche through a pharmacological approach that does not 
involve the administration of VEGF. In this perspective it appears interesting that in 
parallel to the activation of HIF-1 responsible for the induction of the synthesis of 
VEGF, in response to cerebral ischemia there is also a significant activation of 
autophagy (Wen, Sheng et al. 2008).  
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I.2. Autophagy, mechanism and molecular pathway 
Autophagy as a new term was introduced in the 1963 by Christian de Duve, a Belgian 
biochemist who previously had discovered lysosomes and peroxisomes. Autophagy is 
an orchestrated process useful to eliminate unwanted proteins and damaged 
organelles and intracellular microbial pathogens. This mechanism is involved in 
biological and physiological cellular processes such as cellular differentiation and 
development. It has a double possible significance because if it can contribute to cell 
death, on the other it can also represent an important protective factor because it 
provides energy for cell survival in conditions of energy deprivation. At least three 
different forms of autophagy have been identified: the “Microautophagy”, the 
“Chaperone-mediated autophagy” and the “Macroautophagy” as shown with the term 
Autophagy. These forms differing for their function and the mode of delivery of the 
cargo to the lysosomes. Autophagy is a highly controlled process that progresses 
through consecutive steps: Initiation, Nucleation, Elongation, Maturation and 
Degradations. This process is initiated by the activation of ULK1 complex from AMPK 
and inhibited by the TORC1 complex. ULK1 mediates the activation of the PAS 
(Phagophore Assemble Site) which is a specialized intracellular membrane region that 
through a double-membrane known as phagophore is assembled. It’s the precursor of 
autophagosome that through the elongation of this phagophore, forms an omegasome 
and finally closes forming the autophagosome. An ULK1 interacting protein, Atg9, acts 
as a lipid cargo system between the ER (Endoplasmic Reticulum) and PAS and provide 
for the lipids during phagophore maturation. In the elongation and maturation of the 
phagophore in the autophagosome, it’s required ULK1 mediated activation of the 
PI3KIII complex and directs the assembly and activation of two ubiquitin like system: 
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the Atg5/atg12 system and LC3 system. After activation, LC3 is first cleaved in two 
fragments: LC3-I and LC3-II and the latter is involved in a reaction requiring Atg12-
Atg5-Atg16L complex that concludes for the omegasome closure with the formation of 
a mature autophagosome containing cell components committed to lysosomal 
degradation (Xie and Klionsky 2007). Finally, it fuses with lysosomes to form 
autolysosome where degradation begins (Figure 6) (Klionsky, Abdelmohsen et al. 
2016, Yin, Pascual et al. 2016).  
 
 
 
Figure 6. Schematic representation of the pathway of autophagy (Yu, Chen et al. 2018). 
 
I.2.1. The machinery of autophagy: role of Beclin1, LC3 and Atg5  
As described in the previous paragraph, the autophagy evolves in distinct step in which 
different proteins are involved assuming an importance as a marker for study this 
biological process. Among them, Beclin1 is involved in the nucleation step, it’s the 
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orthologue of yeast Atg6 and has a major role in the identification of the localization of 
the PAS. Beclin1 together with AMBRA1 (Activating molecule in beclin1 regulated 
autophagy) forms a complex with VPS15 and VPS34 called PI3KC3 (class III 
phosphatidylinositol 3-kinase) (Figure 7) that by a phosphorylation produces PI3P 
(Phosphatidylinositol-3-phosphate) essential for the autophagosome formation along 
with the other proteins involved in this process as the complex Atg12-Atg5 and Atg16-
L1 (Kang, Zeh et al. 2011). In particular Beclin-1 has been identified as an interactor 
of the anti-apoptotic protein Bcl2 that negatively regulates autophagy (Levine, Sinha 
et al. 2008). In the step of elongation, as shown in figure 7, LC3 has an important role 
in the autophagosome formation. This protein exists in two forms that are known as 
LC3-I and LC3-II. The first is the complete protein, while the second is incomplete of 
an amino acid sequence and is a carrier of the PE (Phosphatidylethanolamine). 
Through the PE, LC3 is associated with the vesicle that being formed. When the 
synthesis process is completed, LC3 is removed from the outer membrane and 
recycled while that is located in the inner membrane will be degraded together it. This 
protein is the most used as an autophagosome marker (Kabeya, Mizushima et al. 
2000, Kimura, Noda et al. 2007, Kimura, Fujita et al. 2009). Furthermore, Atg5 is 
essential for the extension of the autophagosomal membrane and it is coordinated with 
the conjugation system as LC3-PE complex (Figure 7). The Atg5-Atg16L1-Atg12 
complex is the first direct to the expansion and curvature of the autophagosome 
membrane during formation. LC3 is initially cut off from the Atg4 protease. After the 
LC3 process, the Atg5-Atg16L1-Atg12 complex dissociates from the membrane just 
before completion of autophagosome formation and LC3 II continues it process 
(Mizushima, Sugita et al. 1998, Kabeya, Mizushima et al. 2000).  
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Figure 7. The molecular pathway of autophagy: It is showed how the regulation of autophagy is 
determined by specific proteins in each step: Initiation, Nucleation, Elongation (Galluzzi, Bravo-San 
Pedro et al. 2017). 
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I.2.2. Interest in the pharmacological modulation of the autophagy 
It becomes interesting to consider that the biochemical reactions involving all the steps 
of the autophagic cascade recruit at least 100 different proteins (Noda and Inagaki 
2015). Therefore, it’s of particular interest to study the autophagy process through the 
specific drugs directed on proteins involved in each step of the autophagic cascade 
(Figure 8) (Galluzzi, Bravo-San Pedro et al. 2017).  
 
 
 
Figure 8. A synthetic representation of the drugs that act selectively in each step of autophagy 
cascade: The drugs are grouped as follows: in the blue panels are represented the inhibitor drugs for 
autophagy whereas in orange the drugs activators of autophagy. And in each panel, there are 
represented the protein target for the drugs listed in the panel (Galluzzi, Bravo-San Pedro et al. 2017). 
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As shown in Figure 8, during the first step of Initiation, one of the drugs used for the 
activation of autophagy is the Metformin that is a well known pharmacological 
compound largely used to treat type 2 diabetes mellitus (DM2) and this drug is of 
particular interest for its ability to activate the AMPK cascade (Zhou, Myers et al. 2001, 
Viollet, Guigas et al. 2012, Wrobel, Marek et al. 2017). In fact, the autophagy activation 
by AMPK can be proceeded through two mechanisms: inhibition of mTOR or 
phosphorylation of ULK-1 (Steinberg and Kemp 2009, Villanueva-Paz, Cotan et al. 
2016). In the phase following initiation, that is named nucleation, several researchers 
have shown that it can be inhibited by drugs as LY290042 or 3MA through an inhibition 
mechanism of the class III PI3K complex that is required for the formation of PAS 
(Caro, Plomp et al. 1988, Blommaart, Krause et al. 1997, Stroikin, Dalen et al. 2004, 
Wu, Tan et al. 2010, Zou, Zhang et al. 2014). More, in the step before the degradation, 
the lysosome is fused with the autophagosome exposing the organelles and 
compounds to the degradation caused by the action of the lysosomal hydrolases. In 
this phase, the Chloroquine acts with a mechanism of prevention of the endosomal 
acidification. It accumulates in the lysosomes causing an increase in lysosomal pH, 
which inhibits lysosome function and may block fusion of the autophagosome with the 
lysosome (Beil, Staar et al. 1992, Beil, Sewing et al. 1999). Or the Bafilomycin 
(Hanada, Moriyama et al. 1990, Oda, Nishimura et al. 1991) and Pantoprazole 
(Moreira Dias 2009, Vegger, Bruel et al. 2017) that are two inhibitors of the Vacuolar 
H+ATPase, which controls the pH in the lysosome and causing an elevated lysosomal 
pH preventing the acidification of endosomes and lysosomes inhibiting the autophagic 
flux. Furthermore, there are still experimental obstacles that do not allow 
pharmacological modulation in the clinic. In the light of these evidences, it is of 
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considerable interest to identify and creating selective autophagy modulators and 
specific biomarkers for the autophagic flux (Galluzzi, Bravo-San Pedro et al. 2017). 
 
I.2.3. Relevance of autophagy in response to cerebral ischemia 
Autophagy is activated in conditions of nutrients and oxygen deprivation and help cells 
to survive by recycling part of their components. More recently, relevant implications 
of autophagy in diseases progression have been described. In particular, autophagy is 
involved in neurodegenerative diseases, in microbial infections, in aging and in obesity 
(Kimura, Isaka et al. 2017, Qian, Fang et al. 2017). Recent evidence suggests that 
autophagy could also have a prominent role in vascular biology (Nussenzweig, Verma 
et al. 2015) where it has been shown that autophagy has a protective role against 
atherogenesis, that it’s essential for the increase in nitric oxide (NO) production 
induced by shear stress and consequently, an impairment of autophagy leads to 
endothelial dysfunction. So far, contrasting data have been accumulated on the role of 
autophagy in angiogenesis because some studies suggested that it inhibits and other 
that it stimulates this process. Antiangiogenic factors seem to exert their effects by 
inducing autophagy. An increase in autophagic flux has been observed upon exposure 
to dermatan proteoglycan decorin that inhibits KDR/VEGFR2 and increases the 
expression of PEG3/PW1 a transcription factor that controls the transcription of Beclin1 
and LC3 (Buraschi, Neill et al. 2013, Neill, Torres et al. 2013) and this antiangiogenic 
factor also activates AMPK. Some evidence suggests that autophagy is required for 
angiogenesis during development.  
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I.2.4. The possible role of the autophagy in the angiogenesis after a stroke 
After a stroke, different signals are triggered in response to the damage in order to try 
to restore the physiological conditions of nutrients and oxygen in the area of injury. 
When a reduction of blood flow occurs, the angiogenic signals are stimulated for to 
activate the angiogenic sprouting and new vessels will form. As the hypoxia activates 
the VEGF pathway, in turn it activates the autophagy process able to sustain cell 
survival. Although many studies on the angiogenesis were performed on the low 
nutrient conditions, there are still several studies that investigate the angiogenesis 
under nutrient deprivation. It’s well known that autophagy is a biological process of 
degradation that is fundamental for the cell survival in low nutrient-deprived conditions 
(Du, Teng et al. 2012). Recent studies reported evidences that autophagy is involved 
in angiogenic activation in conditions of nutrient deprivations, and that if the 
angiogenesis is inhibited there is an increase in autophagy signals (Nguyen, 
Subramanian et al. 2007, Ramakrishnan, Nguyen et al. 2007). Nowadays it is unknown 
whether autophagy has a role on the endothelial cells in angiogenesis. It is become 
interesting the study of the expression of proteins involved in the autophagic pathway 
after an ischemic insult (Rami, Langhagen et al. 2008, Dai, Xu et al. 2017, Wang, Shao 
et al. 2018). As Beclin1 is the protein involved in the initial process of autophagy, it can 
be a marker to evaluate the initial involvement of autophagy in the stroke by the 
reparative processes carried out by angiogenesis. The complicated pathway of 
autophagy not help to investigate the specific phases of angiogenesis on in vitro and 
in vivo so it is still a mystery to clarify whether autophagy plays a role in angiogenesis.   
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II.  AIM OF THE STUDY 
After ischemic stroke and brain injury, angiogenesis occurs to restore tissue perfusion 
by developing new vessels (Beck and Plate, 2009). VEGF was traditionally regarded 
as the primary factor activated in the angiogenic reparation and it has been proposed 
as a therapeutic tool for neurodegenerative diseases (Zhang, Zhang et al. 2000). 
Contrary to the expectations, VEGF is discouraged in the use as a therapeutic drug for 
its pharmacokinetic limitations and its potential to induce toxicity. From these reasons, 
researchers are looking for an alternative mechanism able to modulate angiogenesis 
in the central nervous system independent from the pathway of VEGF. Since the 
hypoxia has been widely characterized as a powerful stimulus for the activation of the 
angiogenic process and as an inducer of the autophagic cascade, the aim of the 
present thesis has been to determine whether autophagy represents a control of the 
angiogenic mechanism in alternative to VEGF. Preliminary studies are focusing on the 
role played by endothelial cells bEND5 in angiogenesis. These cells have the 
peculiarity to form a capillary like network in the absence of exogenous VEGF.   
In details, the aims of the present thesis work have been: 
• To investigate the effects of drugs acting on the autophagic cascade on capillary 
tubule formation in vitro. 
• To evaluate the expression of autophagic proteins: Beclin-1 and LC3, in cell 
cultures after specific pharmacological modulation. 
• To investigate the time course of Beclin-1 expression after endothelial cell 
seeding on Matrigel with confocal. 
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• To investigate whether also autophagosome is activated during tubule 
formation. For that reason, we treated the bEND5 cells with Monodansylcadaverine a 
fluorescent compound selectively incorporated in activated autophagosomes by both 
an ion trapping mechanism and by the interaction with membrane lipids.  
• To evaluate the effects on the silencing of the key gene involved in the 
autophagy pathway by silencing Atg5 in bEND5 cells.  
• To perform immunocytochemical analysis of Beclin1 and CD31 expression in 
the cerebral cortex at different times point after tMCAO and ischemic preconditioning. 
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III.  MATERIALS AND METHODS 
 
III.1. Drugs and chemicals 
To validate bEND5 as a model of VEGF independent cell line for the study of 
angiogenesis, the drug Bevacizumab was used (purchased from Roche 
Pharmaceutical). For experiments on the pharmacological modulation of autophagic 
cascade during tubulogenesis in vitro, the following drugs were used: the antidiabetic 
drug Metformin hydrochloride (Cod.PHR1084) (purchased from Sigma Aldrich); an 
inhibitor of the PI3K complex in the autophagy, namely 3-Methyladenine (3-MA) 
(Cod.M9281) (purchased from Sigma Aldrich); another inhibitor of autophagy with the 
same mechanism as observed for 3-MA, LY294002 (Cod.L9908) (purchased from 
Sigma Aldrich); Chloroquine diphosphate salt (Cod.C6628), Bafilomycin A1 from 
Streptomyces (Cod. B1793) and Pantoprazole sodium hydrate (Cod.P0021) (all 
purchased from Sigma Aldrich). For the assay of tubulogenesis in vitro, Geltrex™ 
LDEV-Free Reduced Growth Factor Basement Membrane Matrix (purchased from 
InvitrogenTM /Thermo Fisher Scientific) were used. The siRNA used for the Atg5 
silencing were Atg5MSS247019 (RNA) -(5’GCGAGCAUCUGAGCUACCCAGAUAA3’) 
and Atg5MSS247019 (RNA)-(5’UUAUCUGGGUAGCUCAGAUGCUCGC3’) 
(purchased from InvitrogenTM /Thermo Fisher Scientific). The kit for 
Autophagy/Cytotoxicity dual staining detection (purchased from Cayman Chemical 
Company) that contains Monodansylcadaverine, a fluorescent compound that was 
incorporated into multilamellar bodies by both an ion trapping mechanism and the 
interaction with membrane lipids, as a probe for detection of autophagic vacuoles in 
cultured cells (Biederbick, Kern et al. 1995, Munafo and Colombo 2001).  
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III.2. In vitro methods 
 
III.2.1.  Cell culture 
The bEND5 cells were purchased from ECACC (European Collection of Authenticated 
Cell Cultures-cod 96091930). These cells line has been established from brain 
endothelial cells of BALB/C mice by immortalization through the infection of primary 
cells with retrovirus coding for the Polyoma virus middle T-antigen. The bEND5 cells 
possess an endothelial-like morphology, and are testes by fluorescent activated cell 
sorting (FACS), are positive for endothelial specific proteins (PECAM-1, Endoglin, 
MECA-32, FIK-1) (Yang, Roder et al. 2007, Steiner, Coisne et al. 2011). bEnd5 cells 
are well distinguished for its expression of EC specific proteins, such as the vascular 
endothelial-cadherin (VE-cadherin), von Willebrand factor, PECAM-1 (platelet 
endothelial cell adhesion molecule-1), endoglin, ICAM-2, and claudin-5. Nonetheless, 
despite previous studies indicating the expression of occludin in brain ECs, it’s still in 
question since a study by Steiner et al. (2011) found a significant decrease in occludin 
mRNA expression in bEnd5 cells when compared to primary mouse brain 
microvascular endothelial cells (pMBMECs). Cytokines induce the expression of 
protein such as (CAM-1, V-CAM-1 and E-Selectin) and have endothelial-like 
morphology. Injection of this cell line into mice causes development of haemangiomas. 
These cells express BBB markers like GLUTs, P-glycoprotein, Na+/K+/Cl cotransporter, 
occludin and the tight junction protein 1, ZO-1 and form BBB-like polarized monolayers 
in vitro. The important feature of these cells is that form blood vessels in vitro.  
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The bEND5 grows in the Dulbecco’s Modified Eagle’s Medium (DMEM) with 2mM L-
Glutamine, 1mM Sodium Pyruvate (NaP), 1% Minimal Essential Medium MEM, 10% 
Fetal Bovine Serum (FBS), 50 Units/mL penicillin, and 50 μg/mL streptomycin. At 
confluence, cells were trypsinated using 0.25% EDTA-trypsin (Whitehead Scientific, 
BE02-007E). bEnd5 culture conditions for cell growth was 37°C with 95% humidity and 
5% CO2. When bEND5 cells are plated on plastic culture dishes they are grow as a 
monostrate culture; they are showing a cobbled appearance similar to that of well 
differentiated endothelial cells. At confluence the culture virtually covered the entire 
surface of the dish. Most of the cells were elongated or fusiform. An aspect can be 
noticed when we plated on multiwell coated with extracellular matrix Geltrex™ LDEV-
Free Reduced Growth Factor Basement Membrane Matrix, bEND5 cells formed a well 
differentiated capillary-like network. Since the first two/three hours from plating, the 
cells started to arrange in strings around central holes though they were still rounded. 
Well defined capillary structures were evident at 22 hours from plating (DeCicco-
Skinner, Henry et al. 2014).  
 
III.2.2. In vitro tubulogenesis 
The angiogenesis can be studied on in vitro methods that consist of mimicking the 
growth of endothelial cells in a matrix allowing the development of tubules (Folkman 
and Haudenschild 1980, Staton, Stribbling et al. 2004, DeCicco-Skinner, Henry et al. 
2014, Nowak-Sliwinska, Alitalo et al. 2018). The experiments performed on in vitro 
tubulogenesis were performed to evaluate the vessel formation treated with drugs that 
act on different steps of autophagic cascade. Before the experiment, the 96 multiwell 
plate and plastic tips were kept overnight at -20° and Geltrex™ Matrigel was thawed 
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by keeping it in ice in the cold room overnight. In the day of experiment. The Geltrex™ 
LDEV-Free Reduced Growth Factor Basement Membrane Matrix purchase from 
InvitrogenTM /Thermo Fisher Scientific); 40 µl of Geltrex were gently and 
homogeneously dispensed on the bottom of each well avoiding bubbles. The matrix 
was left to gel by leaving the multiwell at 37°C for 30 minutes in a 5% CO2 incubator. 
In the meanwhile, bEND5 cells were plated in each well, approximately 85.000 cells in 
the presence of vehicle for the control and with the appropriate concentration of the 
test drug that were: Metformin hydrochloride that the stock solution used is prepared 
at the concentration of 10 mM and through dilutions with the bEND5 medium were 
obtained the concentrations of 3 and 1 mM; 3-Methyladenine an inhibitor of the PI3K 
complex in the autophagy, the stock solution is prepared at 10 mM and through 
dilutions with the bEND5 medium were obtained the concentrations of 3 and 1 mM; 
LY294002 is another inhibitor of autophagy with the same mechanism of the 3-
Methyladenine, this drug is prepared by a stock solution of 25mM dissolved in a 
solution of DMSO and from this were prepared the solutions of 100, 30 and 10 µM 
through a dilution with bEND5 medium. Chloroquine with a stock solution of 30 µM and 
through dilution with bEND5 medium were prepared concentrations of 3 and 1mM. 
Bafilomycin was prepared by a stock of 100µM dissolved in DMSO and from this there 
were prepared the concentrations of 100, 10 and 1 nM with dilution by bEND5 medium. 
The Pantoprazole stock solution was prepared at the concentration of 1mM, and by 
dilution there were obtained the concentrations of 0,3 and 0,1 mM. Experiments were 
performed on individual multiwell for each drug used. Unless otherwise specified, 
microphotographs for image analysis were taken at 4X magnification 22 h after plating. 
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III. 2.2.1 Statistical analysis of in vitro vessel formation 
The results related to the effect of the different pharmacological treatments on capillary 
network formation was analyzed using the Image J software which can be downloaded 
for free from the website http://rsbweb.nih.gov/ij/. This software program can analyze 
and measure specific parameters defined with the name of shape descriptors that 
include: tubule number/field, cumulative area of the lumina/field, mean tubule 
circularity, mean tubule solidity. The tubule number/field indicates the number of 
vessels that are formed with the pharmacological treatments; the cumulative area 
gives a better idea on how diffuse is tubule formation in the microscope field; the 
circularity is represented by this formula: 4π * 
[𝐴𝑟𝑒𝑎]
[𝑃𝑒𝑟𝑖𝑚𝑒𝑡𝑒𝑟]2
. A circularity value of 1 
indicates a perfect circle. The closest is the value to 0 the more elliptical is the shape; 
the solidity is represented by this formula: 
[𝐴𝑟𝑒𝑎]
[𝐶𝑜𝑛𝑣𝑒𝑥 𝑎𝑟𝑒𝑎]
. The convex hull or convex 
envelope of a set X of points in the Euclidean plane is the smallest convex set that 
contains X; solidity is a measure of asymmetry. For a complete guide see the website: 
http://rsbweb.nih.gov/ij/. 
 
III.2.3.  Western Blot on cells 
After drug treatment of bEND5, the cells were washed in phosphate-buffered saline 
(PBS) and collected by gentle scraping in ice-cold lysis buffer containing (in mM): 20 
Hepes pH 7.4, 1 sodium azide, 0.2 sodium orthovanadate, 0.05 sodium fluoride, 1% 
TRITON X-100, and a protease inhibitor cocktail (0.1% aprotinin, 0.7 mg/ml pepstatin, 
1 μg/ml leupeptin) (Roche Diagnostic, Monza, Italy). Samples were cleared by 
centrifugation and supernatants were used for Western Blot. Protein concentration in 
supernatants was determined by Bradford method (Bradford, 1976). Protein samples 
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were loaded and separated on 10% (for Beclin-1) or 15% (for LC3) SDS-
polyacrylamide gels. Proteins were transferred onto Hybond-ECL nitrocellulose 
membrane (GE Healthcare, Little Chalfont, UK). The filters were blocked for 1h at room 
temperature with a blocking solution composed of 5% non-fat dry milk (Bio-Rad 
Laboratoires) in TBS-T (2mM Tris-HCl, 50 mM NaCl, pH 7.5 plus 0.1% Tween20) and 
were then incubated with the appropriate primary antibody dissolved in 5% non-fat dry 
milk. Primary antibodies were used at the following final diluitions: 1:1000 for the 
polyclonal rabbit anti Beclin1 antibody, 1:1000 for the polyclonal rabbit anti LC3 
antibody were purchased from the Sigma Aldrich. After overnight incubation with the 
primary antibody, the membranes were washed with 0.1 Tween20 and incubated with 
the appropriate secondary antibodies dissolved in 5% non-fat dry milk (1:1000) for 1h. 
Immunoreactive bands were detected with the ECL (Amersham). The optical density 
of the bands was measured was determined using a Chemi Doc Imaging System 
(Biorad). Optical density data were normalized to the density of α-Tubulin in the case 
of the LC3, or β-actin in the case of Beclin1 using the ImageJ software for the density 
analysis. 
 
III.2.4.  MTT assay 
Assessment of cell proliferation ability was performed according to the MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide] assay. The cells were 
seeded in a 24-well plate at a density of 130.000 cells/well, three parallel wells for 
group. The cells were divided into control and drug groups according to the different 
concentrations tested. The cells were pretreated with the drugs as indicated here 
before: Metformin hydrochloride was used from a 10mM stock solution through 
- 35 - 
 
dilutions with the bEND5 medium to reach the final concentrations of 3 and 1 mM; 3-
Methyladenine, an inhibitor of the PI3K complex in the autophagy, whose stock 
solution was 10 mM and through dilutions with the bEND5 medium the concentrations 
of 3 and 1 mM were obtained; LY294002 is another inhibitor of autophagy with the 
same mechanism of the 3-Methyladenine, whose stock solution was prepared by a 
concentration of 25mM dissolved in DMSO and from this stock, the diluted solutions of 
100, 30 and 10 µM using bEND5 medium were prepared. Chloroquine was used as a 
stock solution of 30 µM diluted with bEND5 medium to 3 and 1 mM. Bafilomycin was 
prepared by a stock of 100µM dissolved in DMSO and from this stock, the dilutions of 
100, 10 were obtained. The Pantoprazole stock solution was prepared at the 
concentration of 1mM, and then diluted to 0,3 and 0,1 mM. At 22 hours after incubation, 
the medium was aspirated and 0,5 mg/ml MTT (Sigma) was added to the wells, and 
the cells continue to be incubated for 2 h. After this, formazan salt in the well was 
dissolved with 500 μl dimethylsulfoxide (Sigma). Absorbance values were determined 
at 595 nm with BioPhotometers and the cells viability was evaluated. 
 
III.2.5.  Confocal microscopy analysis 
bEND5 cells, after 22 hours from tubulogenesis in vitro using the protocol described 
previously for the vessel formations, were fixed in 4% paraformaldehyde for 20 min at 
room temperature and blocked in 1x PBS, 0.25% Triton X-100 (v/v), and 3% bovine 
serum albumin (BSA). Cells were subsequently incubated with anti-Beclin-1 antibody 
overnight at 4°C. Secondary antibody goat anti-rabbit was used. Nuclear counter stain 
was visualized with DAPI (4,6-diamidino-2-phenylindole, 0.5 μg/ml). The Beclin-1 
immunofluorescence was visualized using an Olympus multiphoton FV-1000 MER 
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microscope with Argon laser 488 nm line and diode laser 405 nm line. The images 
were taken with a UPlanSApo 10-60X/1.35W objective lens. 
 
III.2.6.  Autophagy/Cytotoxicity dual staining test 
bEND5 cells after seeding on matrigel (Geltrex) as described in a previous paragraph, 
are treated following the protocol of the kit (purchased from Cayman) and were 
immediately analyzed by fluorescence microscopy. Dead cells can be detected with a 
fluorescent filter usually designed to detect Rhodamine (excitation/emission= 540/570 
nm). Autophagic vacuoles stained by MDC can be detected with a UV filter usually 
designed to detect DAPI. The images were taken with a DMI4000 B Inverted 
Microscope from Leica 20X objective lens. 
 
III.2.7.  Silencing of Atg5 
Silencing of ATG5 in bEND5 cells was performed by using the standard protocol of 
transfection, by using two different siRNA for Atg5, Atg5MSS247019 (RNA) -
(5’GCGAGCAUCUGAGCUACCCAGAUAA3’) and Atg5MSS247019 (RNA) - 
(5’UUAUCUGGGUAGCUCAGAUGCUCGC3’) purchased from (InvitrogenTM /Thermo 
Fisher Scientific). Cells were incubated with DMEM (Sigma) supplemented with the 
Dharmafect Transfection (Invitrogen) and 5 nM of each siRNA for 72h and 96h 
following the protocol. After the time of incubation, the cells were trypsinated and re-
plated on matrigel for tubulogenesis procedure as previously described. Unless 
otherwise specified, microphotographs for image analysis were taken at 4X and 10X 
magnification 72 and 96h after plating. For an optimal confirm there were performed 
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experiments of western blot for evaluate the expression of Atg5 in the cells after 
transfection. 
 
III.3. In vivo experiments 
To compare the expression of the proteins Beclin1 and CD31 in different experimental 
conditions like ischemia (tMCAO), preconditioning (PC) and ischemic preconditioning 
(PC + tMCAO) at different time points, we have been planned the following 
experimental groups:  
o Group1: 8 rats sham subjected to sham intervention and sacrificed. Brain 
samples of ischemic cortex was collected. 
o Group 2: 8 rats subjected to tMCAO and sacrificed 12 hours after the cerebral 
reperfusion. Brain samples of ischemic cortex was collected.  
o Group 3: 8 rats subjected to tMCAO and sacrificed 24 hours after the cerebral 
reperfusion. Brain samples of ischemic cortex was collected.  
o Group 4: 8 rats subjected to ischemic preconditioning and sacrificed 12 hours 
after the cerebral reperfusion. Brain samples of ischemic cortex was collected.  
o Group 5: 8 rats subjected to ischemic preconditioning and sacrificed 24 hours 
after the cerebral reperfusion. Brain samples of ischemic cortex was collected.  
o Group 6: 8 rats subjected to ischemic preconditioning and tMCAO and 
sacrificed 12 hours after the cerebral reperfusion. Brain samples of ischemic cortex 
was collected.  
o Group 7: 8 rats subjected to ischemic preconditioning and tMCAO and 
sacrificed 24 hours after the cerebral reperfusion. Brain samples of ischemic cortex 
was collected. 
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III.3.1.  Transient Middle Cerebral Artery Occlusion model (tMCAO) 
Rats were subjected to surgical procedure as previously described (Longa, Weinstein 
et al. 1989). Before the surgical intervention, the animals were anesthetized with a 
gaseous mixture containing O2 98% and sevoflurane 2% through a mask connected at 
the vaporized by means a polypropylene tube. The rats under anesthesia were placed, 
in dorsal decubitus, on a heating pad connected with a rectal thermometer in order to 
maintain stable body temperature during the surgical procedure. Then a medial 
incision of about 3 cm on the ventral part of the neck was practiced and, under the 
guidance of a stereomicroscope and with the aid of microsurgical tweezers, the 
muscular plane and the underlying bands were detached until reaching the artery 
common carotid (CCA). Then, through a blunt dissection it was isolated the CCA from 
the vagus nerve and, similarly, from the external carotid artery (ECA) and the right 
internal carotid artery (ICA). Once the vessels were isolated a nylon filament (5-0, 
Ethylon, 19mm long) was inserted into the right internal carotid artery (ICA), at the level 
of the branch from the artery common carotid. The filament was pushed in the cranial 
direction until it reached the branch of the middle cerebral artery (MCA), thus blocking 
the blood flow.  After 100 minutes the animal was anesthetized with the precedent 
gaseous mixture in order to allow the reperfusion to occur by removing the filament. 
  
- 39 - 
 
III.3.2.  Ischemic Preconditioning (IPC) 
Ischemic preconditioning was obtained by 30-minute occlusion of the middle cerebral 
artery using the same procedure above described. 
 
III.3.3.  PC + tMCAO model 
Animals were subjected to the preconditioning by 30 minutes MCA occlusion and, 72 
hours after reperfusion the filament was reinserted and the middle cerebral artery 
thereby reoccluding it for 100 minutes and finally animals were sacrificed at the time 
established for the experimental group. 
 
III.3.4.  Tissue processing and confocal immunofluorescence 
Animals were anesthetized and transcardially perfused with saline solution containing 
0.01 ml heparin and followed by 4% Paraformaldehyde in 0.1 mol/l of PBS saline 
solution. Brains were rapidly removed from the cranium and fixed in the 
Paraformaldehyde overnight at +4°C. The day after the brains are posted in 30% 
sucrose in 0.1 M phosphate buffer (PB) with sodium azide 0.02% for 24 h at 4°C for 
the cryoprotection. When the brains are on the bottom of the container, they were 
sectioned frozen on a sliding cryostat at 40 μm thickness, in rostrum-caudal direction. 
Afterwards, free floating serial sections were incubated with PB Triton X 0.3% and 
blocking solution (0.5% milk, 10% FBS, 1% BSA) for 90 min. The sections were 
incubated overnight at +4 °C with the following primary antibodies: anti-Beclin-1 
1:1000; (Rabbit polyclonal antibody purchased from Abcam, Cambridge, UK), anti-
CD31 1:1000 (mouse monoclonal antibody; purchased from Abcam, Cambridge, UK). 
The sections were then incubated with the corresponding florescent-labeled secondary 
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antibodies, Alexa 488/Alexa 594 conjugated antimouse/antirabbit IgGs (Molecular 
Probes, Invitrogen S.R.L., Milan, Italy).  Nuclei were counterstained with Hoechst 
(Sigma-Aldrich, Milan, Italy). Images were observed using a Zeiss LSM700 
META/laser scanning confocal microscope (Zeiss, Oberkochen, Germany). Single 
images were taken with an optical thickness of 0.7 m and a resolution of 1024 × 1024. 
Quantification of Beclin1, CD31 fluorescence intensity on tissue sections at the level 
of the cortex, was quantified in terms of pixel intensity value by using the NIH image 
software. After, digital images were taken with ×40 or ×10 objective and identical laser 
power settings and exposure times were applied to all the photographs from each 
experimental set. 
 
III.3.5. Statistical analysis  
The data obtained in bEND5 cells experiments were expressed as mean ± standard 
error and statistical significance of differences between groups were performed by 
Two-Way ANOVA analysis followed by Newman Keuls post-hoc test. P-value was set 
to p<0.05. 
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IV. RESULTS 
IV.1. Tubule formation in bEND5 cells is not affected by Bevacizumab-treatment 
bEND5 cells form a well differentiated capillary-like network when plated on multiwell 
coated with extracellular matrix Geltrex™ (Figure 9). 
 
        
 
 
Figure 9. bEND5 cells form capillary-like networks in vitro: A) bEND5 plated on plastic dish, at 
confluence have a cobbled appearance. B) bEND5 plated on plastic dish coated with extracellular matrix 
form a well differentiated capillary-like network. The data are reported as mean ± SEM of n=3 
experiments and the capillary like network formation was observed after 22 hours after seeding on 
Matrigel.  
 
The time for a complete in vitro tubulogenesis is between 22-24 hours from seeding 
on Matrigel. The results show the independence of these cells from the VEGF during 
the vessels formation by the treatment with the anti-VEGF drug, the Bevacizumab 
(Avastin), a humanized monoclonal antibody that bind the VEGF an angiogenic 
stimulator. As widely demonstrated this drug, neutralizes VEGF and blocked its signal 
transduction through VEGF receptors (Wang, Fei et al. 2004, Ferrara, Hillan et al. 
2005). For this experiment, the drug has been tested on bEND5 during in vitro 
A B 
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tubulogenesis, and the microscope analysis was performed at 22 hours that represents 
the time for a complete in vitro tubulogenesis of bEND5, As shown in Figure 10, tubule 
formation in our bEND5 model has been not inhibited in presence of increasing 
concentrations of Bevacizumab. In particular, three different drug concentrations have 
been used 30µg/ml, 100 µg/ml and 300 µg/ml. In addition, to test the hypothesis that 
Bevacizumab treatment could affect the morphology of tubule formation in bEND5 
model it has been performed a set of further experiments (Figure 11). 
 
                  
Figure 10. Effects of Bevacizumab on tubulogenesis in vitro: bEND5 cells plated on multiwell 
coated with extracellular matrigel have been observed upon treatment at different concentration of 
Bevacizumab (30-100-300 µg/ml). Results have been compared to the control were bEND5 cells were 
plated in normal medium.  
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Figure 11. Statistical analysis of tubule formation: As shown in the panels, the concentrations of 
Bevacizumab used in these experiments has not affected in vitro capillary tubule formation at different 
concentrations as shown in the Figure 10. Bevacizumab, an antiVEGF drug not inhibite tubule formation 
in vitro at the concentrations performed for the experiment. The data of these results are reported as 
mean ± SEM of n=4 experiments performed on bEND5. 
 
In order to confirm the validity of our in vitro model for the study of angiogenesis, the 
level of expression of the receptor-1 and 2 for VEGF (VEGFR1 and VEGFR2) were 
evaluated. In bEND5 cells treated with Bevacizumab, the VEGFR1 and VEGFR2 
expression has been compared to the physiological expression from lysates of a cortex 
tissue collected from a brain obtained through extraction procedure from a mouse of 
our work group that was exposed to the Bevacizumab treatment. 
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Figure12. Western Blot on VEGFR expression: As known that VEGF is essential for tubule formation, 
in order to confirm that bEND5 cells express the VEGF receptor, WB analysis has been performed in 
order to evaluate the presence of VEGF in these cells after Bevacizumab treatment in comparison with 
a lysate of a cortex tissue collected from a brain of a mouse exposed to Bevacizumab treatment. In that 
way, the confirmation of the presence of VEGFR-1 and VEGFR-2 in bEND5 cells indicates that, tubule 
formation in these cells are VEGF independent. The data of these results are reported as mean ± SEM 
of n=4 experiments performed on bEND5. 
 
From these results it can be conclude that bEND5 cells are VEGF independent, and 
this represent a valitate experiment model to study angiogenesis in vitro.  
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IV.2. Metformin increases the capillary area during vessel formation in bEND5 
Metformin, an inducer of autophagy acting on AMPK (Zhou, Myers et al. 2001), 
administered at increasing concentrations (1, 3, 10 mM) in cultured bEND5 cells on 
Matrigel, is able to increase the capillary area of new vessels (Figure 13A). The efficacy 
of Metformin treatment has been assessed at by a microscope analysis after 22 hours 
from the exposure to the drug, as previously show. In particular Metformin treatment 
has not affected the other parameters of new tubules formation, as tubule number or 
circularity but only presented an effect on tubule area. This result clearly indicates an 
involvement of Metformin in new tubule formation (Figure 13A).  
 
 
 
A 
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Figure 13. Metformin affects new tubule formation in Bend5 cells: (A) After 22 hours Metformin 
increases tubule area during tubulogenesis as shown in the panel at a concentration of 10mM, this 
evidence indicates that the drug helps the tubule formation in vitro. (B) There is a reduction of tubule 
number at the highest concentration of Metformin, tested (10mM) conversely tubule area results 
increased the same in vitro concentration. The values are expressed as mean ± SEM of 3 experiments 
*p<0.05 versus their respective controls. 
 
To verify which phase of the autophagic cascade is involved in angiogenesis observed 
in our in vitro model of bEND5 cells mimicking BBB, Beclin1 expression levels has 
been observed upon treatment with Metformin. As shown in the Figure 14, Metformin 
at 3mM concentration is strongly expressed in bEND5 cells compared to control cells. 
This evidence clearly indicated that the initiation of autophagic pathway in bEND5 has 
been activated by the drug. 
B 
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Figure 14. Beclin1 expression after Metformin treatment at different concentrations: Beclin1 
expression evaluated by WB after Metformin treatment (A); Beclin1 is increased in bEND5 treated with 
the drug starting from the concentration of 3mM (B). Beclin1 levels are expressed normalized with β-
actin. The values are expressed as mean ± SEM of 3 experiments *p<0.05 versus their respective 
controls. 
 
Further, to dissect the possible involvement of the later stage of autophagy in the 
pharmacological effect of Metformin, able to stimulate an increase in capillary density 
area, LC3 expression has been analyzed. What we found is that the increase in LC3 
levels of expression is similar to that observed for Beclin1 (Figure 15). 
     
 
 
 
Figure 15. LC3 expression after Metformin treatment at different concentrations: (A). LC3 is 
increased in bEND5 treated with the drug starting from the concentration of 3mM (B).  LC3 levels are 
expressed normalized with α-tubulin. The values are expressed as mean ± SEM of 3 experiments. 
*p<0.05 versus their respective controls. 
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In addition, the highest concentration of Metformin (10mM) significantly reduces 
bEND5 cells number, but not causes an increase in cell mortality as shown in the 
Figure 16. 
 
                         
 
Figure 16. Effects of Metformin on cell viability: After 22 hours from the Metformin starting treatment. 
The values are expressed as mean of 4 experiments ± SEM. *p<0.05 versus their respective controls. 
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IV.3. 3-Methyladenine decreases almost all parameters in the vessel formation 
To analyze the capability of a compound, able to block the nucleation step of 
autophagy (Wu, Tan et al. 2010), to reduce new vessel formation during angiogenesis, 
the 3-metil-adenine (3-MA) has been administered at different concentrations (1, 3, 10 
mM) in plated bEND5 cells on Matrigel monitored by microscope analysis after 22 
hours from the beginning of the treatment. As observed in Figure 17, 3-MA treatment 
causes a decrease of bot tubule area, circularity and solidity that are all parameters 
that give a better idea on how is diffused the new vessel formation during angiogenesis. 
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Figure 17. Effects of 3MA on tubule formation: (A) 3MA at 10mM decreases new tubule formation. 
(B) 3-MA at 5- and 10-mM concentration reduced tubule area and tubule solidity during tubulogenesis.  
These data are reported as mean n=3 experiments. The values are expressed as mean ± SEM of 3 
experimental series. *p<0.05 versus their respective controls. 
 
Trying to understand whether LC3 expression, involved in later phases of autophagic 
cascade, could be affected by pharmacological treatment of 3-MA at different 
concentrations, its expression has been detected by Western Blotting experiments 
(Figure 18). 
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Figure 18. LC3 expression at different concentrations of 3MA: (A) LC3 expression evaluated in 
bEND5 22 hours after the treatment with 5 and 10 mM of 3-MA is reduced because autophagy is 
inhibited by 3MA. (B) The given quantization of LC3 is expressed normalized with α-tubulin. These data 
are reported as mean of n=3 experiments. The values are expressed as mean ± SEM. *p<0.05 versus 
their respective controls. 
 
From the WB results, LC3 expression shows a decrease when bEND5 cells are treated 
with 5 and 10 mM of 3-MA, thus indicating that autophagy is inhibited by 3MA also in 
the later stages of in vitro tubulogenesis. At the same time, both 3mM and 10mM do 
not influence significantly the mortality rate of the cells as evidenced by the MTT assay 
performed at 24 hours after the treatment (Figure 19). 
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Figure 19. Effects of 3MA on cell viability: 3-MA does not reduce bEND5 cells number compared to 
the control one. These data are reported as mean of n=3 experiments. The values are expressed as 
mean ± SEM.  
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IV.4. LY294002 decreases all parameters on in vitro tubulogenesis at the high 
concentration 
To confirm the capacity of specific step autophagic inhibitor (es. 3-MA) to block the 
autophagic cascade, and, consequently, new vessels formation, another autophagy 
selective for the nucleation step of autophagy, namely the LY294002 (Blommaart, 
Krause et al. 1997), has been tested in our model of in vitro tubulogenesis. As it is 
shown thereafter, when administered in bEND5 cultures at high concentrations, 
LY294002 induces a decrease of all tubule parameters (Figure 20A and B).  
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Figure 20. Effects of LY294002 on tubule formation: (A) The treatment with 100 µM of LY294002 is 
able to reduce new tubule formation. (B) All parameters related to new tubule formation are modified by 
this concentration of LY294002. The data are reported as mean of n=3 experiments. The values are 
expressed as mean ± SEM of 3 experimental series. *p<0.05 vs controls. 
 
As shown by testing increasing concentration of the compound in order to find the 
effective concentration able to abrupt stop new vessels sprouting from the plated 
bEND5, at 100 µM it is evident a regression on angiogenesis thus indicating that 
autophagy in closely correlated to tubule formation. 
The direct interaction between LC3 and LY294002 has been confirmed by WB 
experiments showing that the drug induced a concentration dependent not significantly 
decrease in LC3 compared to control. This last result supports the hypothesis that 
autophagy is inhibited by LY294002. 
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Figure 21. LC3 expression at different concentrations of LY294002: (A) LY294002 reduces LC3 
expression on bEND5 in bEND5 after 22 hours from the treatment at 5 and 10 mM is reduced because 
autophagy is inhibited by 3MA. (B) The given quantization of LC3 is expressed normalized with α-tubulin. 
These data are reported as mean of n=3 experiments. The values are expressed as mean ± SEM of 3 
experimental series. 
 
Also, in this case, as previously seen for 3MA, it has been verified whether the inhibition 
of the nucleation step of autophagy could be responsible for an increase in cellular 
mortality. The MTT assay, indicate that the drug does not induce an increase in the 
mortality at the higher concentration (Figure 22). 
                                  
Figure 22. Effects of LY294002 on cell viability: LY294002 does not significantly increase bEND5 
cells mortality compared to the control. These data are reported as mean of n=3 experiments. The 
values are expressed as mean ± SEM.   
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IV.5. Chloroquine decreases tubule formation in vitro 
Testing different compounds able to block specific steps of the autophagic cascade, 
we evaluated the effects of Chloroquine, a lysosomotrophic agent that prevents 
endosomal acidification a crucial step of autophagy in vitro tubulogenesis (Beil, Sewing 
et al. 1999). Chloroquine has been administered at different concentrations (3, 10, 30 
µM) in bEND5 cells on Matrigel and their responses to the treatment have been 
registered at 22 hours after. As shown, the highest dose of Chloroquine (30µM), 
decreases the tubule number, the area, the circularity and the solidity of new vessels 
(Figure 23A). 
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Figure 23. Effects of Chloroquine on tubule formation: Chloroquine at the highest dose tested of 
30µM decreases tubule formation interfering with in vitro tubulogenesis (A). The treatment reduces all 
parameters related to new vessel sprouting (B). These data are reported as mean n=3 experiments. 
The values are expressed as mean ± SEM. 
 
The total inhibition of tubule formation caused by 30µM Chloroquine (Figure 23A), 
leads us to support the hypothesis that the drug causes at the same time, by blocking 
autophagy, a worsening of cell viability. Contrary to expectations MTT assay has 
revealed that there is not an increase in mortality rate of cells treated (Figure 24). 
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Figure 24. Effects of Chloroquine on cell viability: Chloroquine does not reduce bEND5 cells 
number compared to the control. These data are reported as mean of n=3 experiments. The values 
are expressed as mean ± SEM.  
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IV.6. Bafilomycin blocks tubule formation in vitro 
Bafilomycin, an inhibitor of the Vacuolar H+ATPase, which controls the pH in the 
lysosome by causing an elevation in lysosomal pH. This phenomenon prevents the 
acidification of endosomes and lysosomes inhibiting the autophagic flux (Oda, 
Nishimura et al. 1991). To verify the contribution of this process in the autophagic 
cascade leading to in vitro tubulogenesis, Bafilomycin has been tested at different 
concentrations (30, 100, 300 nM) in bEND5 cells plated on Matrigel and is the cells 
have been monitored after 22 hours. The drug administered at the doses of 100 and 
300nM decreases tubule formation (Figure 25A) and decreases all parameters useful 
to assess the new vessel formation: the number, the area, the circularity and the 
solidity, in particular at 300nM.  
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Figure 25. Effects of Bafilomycine at different concentrations on tubule formation: (A) After 22 
hours Bafilomycin at gradual concentrations reduces tubule formation as shown at 100nM concentration 
and it’s completely blocked at 300nM (B) At the highest dose of Bafilomycin (300nM) affects all 
parameters, reducing them. These data are reported as mean of n=3 experiments. The values are 
expressed as mean ± SEM.  
 
As evidenced from the Figure 25A, new vessels formation has been completely 
prevented at 300nM probably by the block of a crucial mechanism involved in the 
autophagic cascade, that involved in lysosomal acidification, as described previously. 
Therefore, to confirm that the block or this path is not paralleled by increased mortality, 
MTT revealed the absence of a reduction in cell viability (Figure 26).  
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Figure 26. Effects of Bafilomycine on cell viability: Bafilomycine does not significantly reduce bEND5 
cells number compared to the control. These data are reported as mean n=3 experiments. The values 
are expressed as mean ± SEM.  
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IV.7. Pantoprazole inhibits new tubule formation 
Another inhibitor of the Vacuolar H+ATPase, with the same mechanism described for 
Bafilomycin, is the Pantoprazole (Moreira Dias 2009) that has been administered at 
the concentrations of 0,1 0,3 and 1 mM in bEND5 to prove whether this drug inhibited 
tubule formation (Figure 27A). As expected, Pantoprazole is effective in blocking new 
tubule parameters as the vessel number, the vessel circularity, the vessel area and the 
vessel solidity confirming that these vacuolar H+ATPase inhibitor have a crucial role in 
blocking the autophagic process, thus in turn causing a block in tubule formation. 
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Figure 27. Effects of Pantoprazole on tubule formation: (A) Pantoprazole inhibits tubule formation 
at the highest concentration used. (B) All morphological parameters are reduced at 1mM concentration 
of Pantoprazole. 
 
The reduction of all parameters as in Figure 27A, is not related with the cell mortality 
confirmed by MTT assay (Figure 28).  
                          
 
Figure 28. Effects of Pantoprazole on cell viability: Pantoprazole does not significantly reduce the 
cells number compared to the control. These data are reported as mean n=3 experiments. The values 
are expressed as mean ± SEM.  
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IV.8. Beclin1 is increased in the early stages of in vitro tubulogenesis 
In bEND5 seeded on Matrigel for in vitro tubulogenesis, Beclin1 expression (GFP) is 
increased at 4 hours (Figure 29). This could be interpreted as follows: autophagy is 
initiated, and in that phase, it corresponds to new vessel formation. 
 
                   
                  1 hours after seeding                                         4 hours after seeding                  
 
 
                                       
                                                      24 hours after seeding 
 
 
Figure 29. Immunofluorescence of Beclin1 (Beclin-green/DAPI-blue) in bEND5 cells: Beclin1 
expression evaluated by confocal staining performed with anti-Beclin1 in bEND5 at 1-4 and 24 hours 
after seeding on Matrigel. Data are reported as mean of n=4 ±SEM.  
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IV.9. The appearance of autophagic vacuoles during vessel formation in vitro 
indicates the link between autophagy and angiogenesis. 
Monodansylcadaverine (MDC),has been widely proposed as a traced for autophagic 
vacuoles (Biederbick, Kern et al. 1995). In preliminary experiments this marker results 
active in bEND5 at 4 hours after seeding on Matrigel (Figure 30). This evidence 
indicates that autophagosome is it is in a late phase of formation, although this marker 
when not used in association with specific dyes such as GFP-LC3, does not allow us 
to clearly recognize active autophagosomes. In fact, MDC penetrates into the acid 
compartments of lysosomes, endosomes and autophagosomes at later stages and 
colors them indistinctly. 
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Figure 30. MDC analysis by Cayman KIT: (A) Bright field; (B) Monodansylcadaverine; (C) Propidium 
Iodide; (D) Overlay. The data are reported as mean of n=3 experiments.  
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IV.10. Atg5 is required for in vitro vessel formation  
“Atg5” silencing inhibits vessel formation in vitro as shown in the Figure 31.  
 
                        siRNA scrumble                                                 siRNA Atg5 
               
 
                    siRNA scrumble                                                 siRNA Atg5  
                
 
Figure 31. Atg5 silencing on bEND5 during tubulogenesis in vitro: When bEND5 cells are silenced 
with siRNA scrumble (A) there is a normal tubule formation; when the bEND5 are silenced with siRNA 
Atg5 there were an inhibition of tubulogenesis. These results have been compared with bEND5 plated 
on plate cell culture at the same siRNA used for the tubulogenesis in vitro and the cells were in normal 
conditions (absence of stress). These data are reported as mean of n=3 experiments. The values are 
expressed as mean ± SEM.  
 
When bEND5 have been silenced with siRNA for Atg5 there is an inhibition of vessel 
formation (Figure 31B), consequently there is a correlation between Atg5 required for 
MATRIGEL 
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the elongation step of autophagy and the vessel formation. The efficacy of Atg5 
silencing has been proven by the administration of siRNA scrumble not able to affect 
tubule formation (Figure 31A). Atg5 expression has been analyzed in bEND5 cells for 
to confirm that Atg5 is expressed in these cells without silencing, and we have 
demonstrated that it is expressed in the bEND5 cells (Figure 32).  
 
                                         
Figure 32. Atg5 expression on bEND5: Atg5 expression is reduced on the bEND5 silencing with 
siRNA Atg5. The given expression of Atg5 is confronted with GADPH. Data are reported as mean of 
n=3 experiments ± SEM. 
 
From these data, Atg5 silencing blocks tubule formation in vitro.  
GAPDH 
  Atg5 
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IV.11. CD31 and Beclin-1 are both increased at 12 hours after PC and PC + 
tMCAO  
Beclin1 expression has been assessed by immunofluorescence in sections of 
ipsilesional temporoparietal cortex of ischemic rats subjected to tMCAO, 
preconditioned, and ischemic preconditioned after 12 hours of reperfusion (Figure33).  
 
 
 
Figure 33. Expression of CD31, Beclin and HOECHST markers in cerebral cortex of rat: In these 
panels it has been shown the expression of these marker involved in autophagic pathway (Beclin-1) and 
vessel formation (CD31) to evaluate if there is a relation between both in different experimental groups 
performed.  
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Double fluorescence immunostaining of Beclin and endothelial marker, CD31, 
revealed that in both ischemic preconditioning and PC + tMCAO, beclin and CD31 
immunoreactivity has shown an increase compared to tMCAO and SHAM rats. These 
results suggest that autophagy is activated during vessel formation within 12 hours of 
neuroprotective stimulation delivery (PC + tMCAO). 
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IV.12. Beclin-1 and CD31 are not related to each other at 24 hours from tMCAO 
and PC 
The expression of Beclin and CD31 has been evaluated after 24 hours of reperfusion 
in the ipsilesional temporoparietal cortex of ischemic rats subjected to tMCAO, 
preconditioned and ischemic preconditioned. (Figure 34) As shown in the figure, Beclin 
1 immunoreactivity is increased in PC + tMCAO on the contrary, the immunoreactivity 
of CD31 was decreased. These results suggest that there is no correlation between 
Beclin-1 and CD31 after 24 hours of reperfusion. 
 
Figure 34. Expression of CD31, Beclin and HOECHST markers in cerebral cortex of rat: In these 
panels it has been shown the expression of markers involved in autophagic (Beclin-1) and vessel 
formation (CD31) in order to evaluate if there is a relation between both in different experimental groups 
performed.   
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V. DISCUSSION 
In the present PhD Thesis, it has been demonstrated that autophagy is crucial during 
tubule formation both in vitro and in vivo. Autophagy has a double possible biological 
significance because if in one direction it can contribute to cell death, on the other it 
can also represent an important protective factor because it provides energy for cell 
survival in conditions of energy deprivation. These functions are evolutionarily 
conserved in the autophagy across different species. Indeed, the autophagy has a 
protective role in many diseases, and this protection is activated in particular during 
hypoxia and ischemia conditions. Recent studies have shown that autophagy is 
involved in aortic angiogenesis through the autophagic modulation used to evaluate its 
influence during angiogenesis. It has been shown that drugs able to stimulate 
autophagy have caused an increase in angiogenesis and drugs that inhibit autophagy 
have caused a decrease in angiogenesis (Du, Teng et al. 2012). From these 
evidences, autophagy can be considered as a mechanism involved in angiogenesis 
useful for the survival of all vascularized organs; and it might constitute a validate 
mechanism for to study the angiogenesis triggered after an energy deprivation. A first 
investigation was conducted on the evaluation of the involvement of autophagy in 
angiogenic processes. For this study, we been used the bEND5 cells that are VEGF 
independent during tubulogenesis in vitro. This is a validate model to determine 
whether autophagy is involved in the angiogenic processes. A first step of 
pharmacological modulation has been the pharmacological modulation of the 
autophagy during tubule formation in vitro (Galluzzi, Bravo-San Pedro et al. 2017). 
Among different drugs and compounds used to attest the importance that each phase 
of the autophagic process, the Metformin demonstrated that also the activation of 
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AMPK through the inhibition of mTOR is crucial in the correct evolution of the 
autophagic cascade (Steinberg and Kemp 2009, Viollet, Guigas et al. 2012, Wrobel, 
Marek et al. 2017). The results reported for Metformin -an increase in tubule area that 
is interpreted as an induction of tubule formation- explain this effectiveness in blocking 
the pathway. Moreover, the value of the experimental design of the present thesis 
relies on the in vitro complete monitoring of all steps involved in autophagy; the 
initiation, the elongation, the maturation and the degradation. Both Beclin-1 and LC3, 
the two most reliable markers of autophagy, were monitored during the whole 
experiments. In these treatments these two proteins were evaluated because the drug 
acts in the initial phase of autophagy, the so-called Initiation step, and LC3 is a marker 
for the autophagosome formation, occurring during the last phase. In addition, two 
inhibitors of the nucleation step, that is important for the follow step which is the 
elongation, were used belonging to the class II of PI3K(Caro, Plomp et al. 1988, 
Blommaart, Krause et al. 1997, Stroikin, Dalen et al. 2004, Wu, Tan et al. 2010, Zou, 
Zhang et al. 2014). In addition, it was determined the effect of blocking tubule formation 
by the compounds 3-MA and LY294002 where these two drugs inhibited that phase at 
the high concentrations. The inhibition of tubulogenesis was due for the block of the 
PI3K complex and did not involve an increase of cell mortality due to its toxicity as 
demonstrated by the MTT assay which returned similar results between the treaty 
group and the controls. Decreasing expression of LC3 evaluated after these two 
pharmacological treatments shows that autophagy is inhibited in the maturation phase. 
The final process of the autophagic cascade, notably the process of fusion of the 
autophagosome with the lysosome, was inhibited by the Chloroquine, a 
lysosomotrophic agent, that prevents endosomal acidification. This molecule 
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accumulates in the lysosomes causing an increase in lysosomal pH, which inhibits 
lysosome function and may block fusion of the autophagosome with the lysosome. 
(Beil, Staar et al. 1992, Beil, Sewing et al. 1999). Bafilomycin (Hanada, Moriyama et 
al. 1990, Oda, Nishimura et al. 1991) and Pantoprazole are two inhibitors of the 
Vacuolar H+ATPase, which controls the pH in the lysosome and causing an elevated 
lysosomal pH prevent the acidification of endosomes and consequently they inhibit the 
autophagic flux through lysosomes fusion. Therefore, the first part of the thesis allows 
to speculate that the autophagy is activated at the early stages of new blood vessels 
formation in vitro as confirmed by the Beclin-1 immunofluorescence experiments. In 
the later stages of autophagy, to monitor the autophagosome formation, experiments 
with monodansylcadaverine (MDC), a probe for detection of autophagic vacuoles in 
cultured cells, have been performed. MDC is an interesting tool to evaluate the trace 
of autophagosome formation, at the level of elongation step; unfortunately, MDC 
detection does not give a secure information about autophagosome formation because 
as described recently, MDC is charged into acid compartments then it colors 
lysosomes, endosomes and in this manner it evidences the late stage of 
autophagosomes (Klionsky, Abdelmohsen et al. 2016). However, this marker is useful 
to monitor autophagy when used in association with specific dyes or labeled proteins 
as GFP-LC3, a green fluorescent protein fused with LC3, that it’s utilized for monitoring 
the autophagy flux (Kabeya, Mizushima et al. 2000, Klionsky, Abdelmohsen et al. 
2016). A colocalization of MDC with GFP-LC3 is indicative of the autophagosome 
formation. Another method used in the present Thesis to investigate if the 
autophagosome formation is involved during tubule formation is to silence a key gene 
involved in this autophagic step. For this aim we performed experiments with the 
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silencing of Atg5 that is an important protein involved in the elongation step of 
autophagy in which the vessel formation is blocked, and its required for the vessel 
formation in vitro.and the interest results were shown with the Atg5 silencing that 
prevent the tubule formation. The need to validate the working hypothesis of the 
present research in a more complex system compared to cultured BEND5 cells has 
encouraged us to switch to an in vivo system. The idea was to find a correlation 
between neoangiogenesis observed in ischemic tissue after the neuroprotection 
conferred by preconditioning (Prec + tMCAO) and angiogenesis in suffering tissue 
imagined as a strategy started by those cells suffering from an ischemic insult, trying 
to overcome it with less energy expenditure as possible. In this field we found that at 
early stages after ischemic preconditioning (12 hours) there was a close correlation 
between the autophagic cascade and new endothelial formation, significant for an 
angiogenic process occurring (Rami 2008, Rami, Langhagen et al. 2008). This 
correlation was left at later stages (24 hours) where usually, according to our 
experience, the best neuroprotection by this model take places. This evidence led has 
to believe that autophagy is tightly linked to neoangiogenesis at early time points, from 
6 to 12 hours, inducing a savage of ischemic penumbra; this contribution of autophagy 
in the rescue of the suffering tissue surrounding the ischemic core is left at 24 hours, 
where probably other mechanisms or pathways take please so as to consolidate 
neuroprotection. Collectively these in vivo results have shown that autophagy is one 
of the first activated pathways when ischemia is preceded by a non-injurious stimulus, 
preconditioning (PC + tMCAO) so as to give the so-called ischemic tolerance. 
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